<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31548223</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2157-1422</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Cold Spring Harbor perspectives in medicine</Title><ISOAbbreviation>Cold Spring Harb Perspect Med</ISOAbbreviation></Journal><ArticleTitle>Predictive Genetic Counseling for Neurodegenerative Diseases: Past, Present, and Future.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">a036525</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/cshperspect.a036525</ELocationID><Abstract><AbstractText>Predictive genetic counseling for neurodegenerative diseases commenced with Huntington's disease (HD). Because the psychological issues and outcomes have been best studied in HD, the HD genetic counseling and testing protocol is still accepted as the gold standard for genetic counseling for these diseases. Yet, advances in genomic technology have produced an abundance of new information about the genetics of diseases such as Alzheimer's disease, frontotemporal dementia, amyotrophic lateral sclerosis, and Parkinson's disease. The resulting expansion of genetic tests together with the availability of direct-to-consumer testing and clinical trials for treatment of these diseases present new ethical and practical issues requiring modifications to the protocol for HD counseling and new demands on both physicians and genetic counselors. This work reviews the history of genetic counseling for neurodegenerative diseases, its current practice, and the future direction of genetic counseling for these conditions.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Cold Spring Harbor Laboratory Press; all rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goldman</LastName><ForeName>Jill S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University Vagelos College of Medicine, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cold Spring Harb Perspect Med</MedlineTA><NlmUniqueID>101571139</NlmUniqueID><ISSNLinking>2157-1422</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005817" MajorTopicYN="N">Genetic Counseling</DescriptorName><QualifierName UI="Q000941" MajorTopicYN="N">ethics</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31548223</ArticleId><ArticleId IdType="pmc">PMC7328452</ArticleId><ArticleId IdType="doi">10.1101/cshperspect.a036525</ArticleId><ArticleId IdType="pii">cshperspect.a036525</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahn TB, Kim SY, Kim JY, Park SS, Lee DS, Min HJ, Kim YK, Kim SE, Kim JM, Kim HJ, et al. 2008. &#x3b1;-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology 70: 43&#x2013;49. 10.1212/01.wnl.0000271080.53272.c7</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000271080.53272.c7</ArticleId><ArticleId IdType="pubmed">17625105</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcalay RN, Dinur T, Quinn T, Sakanaka K, Levy O, Waters C, Fahn S, Dorovski T, Chung WK, Pauciulo M, et al. 2014. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol 71: 752&#x2013;757. 10.1001/jamaneurol.2014.313</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.313</ArticleId><ArticleId IdType="pmc">PMC4082726</ArticleId><ArticleId IdType="pubmed">24756352</ArticleId></ArticleIdList></Reference><Reference><Citation>Almqvist EW, Bloch M, Brinkman R, Craufurd D, Hayden MR. 1999. A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. Am J Hum Genet 64: 1293&#x2013;1304. 10.1086/302374</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/302374</ArticleId><ArticleId IdType="pmc">PMC1377865</ArticleId><ArticleId IdType="pubmed">10205260</ArticleId></ArticleIdList></Reference><Reference><Citation>Almqvist EW, Brinkman RR, Wiggins S, Hayden MR; Canadian Collaborative Study of Predictive Testing. 2003. Psychological consequences and predictors of adverse events in the first 5 years after predictive testing for Huntington's disease. Clin Genet 64: 300&#x2013;309. 10.1034/j.1399-0004.2003.00157.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1399-0004.2003.00157.x</ArticleId><ArticleId IdType="pubmed">12974735</ArticleId></ArticleIdList></Reference><Reference><Citation>American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease. 1995. Statement on use of apolipoprotein E testing for Alzheimer disease. J Am Med Assoc 274: 1627&#x2013;1629. 10.1001/jama.1995.03530200063039</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1995.03530200063039</ArticleId><ArticleId IdType="pubmed">7474250</ArticleId></ArticleIdList></Reference><Reference><Citation>Axelrud LK, Santoro ML, Pine DS, Talarico F, Gadelha A, Manfro GG, Pan PM, Jackowski A, Picon F, Brietzke E, et al. 2018. Polygenic risk score for Alzheimer's disease: implications for memory performance and hippocampal volumes in early life. Am J Psychiatry 175: 555&#x2013;563. 10.1176/appi.ajp.2017.17050529</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2017.17050529</ArticleId><ArticleId IdType="pmc">PMC6372950</ArticleId><ArticleId IdType="pubmed">29495896</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig SS, Strong M, Rosser E, Taverner NV, Glew R, Miedzybrodzka Z, Clarke A, Craufurd D; UK Huntington's Disease Prediction Consortium, Quarrell OW. 2016. 22 Years of predictive testing for Huntington's disease: the experience of the UK Huntington's Prediction Consortium. Eur J Hum Genet 24: 1396&#x2013;1402. 10.1038/ejhg.2016.36</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejhg.2016.36</ArticleId><ArticleId IdType="pmc">PMC5027682</ArticleId><ArticleId IdType="pubmed">27165004</ArticleId></ArticleIdList></Reference><Reference><Citation>Barette J, Marsden CD. 1979. Attitudes of families to some aspects of Huntington's chorea. Psychol Med 9: 327&#x2013;336. 10.1017/S0033291700030841</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291700030841</ArticleId><ArticleId IdType="pubmed">157493</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, et al. 2012. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367: 795&#x2013;804. 10.1056/NEJMoa1202753</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1202753</ArticleId><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, Fanning K, Farlow MR, Hassenstab J, McDade EM, et al. 2017. The DIAN-TU Next Generation Alzheimer's Prevention trial: adaptive design and disease progression model. Alzheimers Dement 13: 8&#x2013;19. 10.1016/j.jalz.2016.07.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.07.005</ArticleId><ArticleId IdType="pmc">PMC5218895</ArticleId><ArticleId IdType="pubmed">27583651</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Stanislaw C, Reyes E, Hussain S, Cooley A, Fernandez MC, Dauphin DD, Michon SC, Andersen PM, Wuu J. 2016. Presymptomatic ALS genetic counseling and testing: experience and recommendations. Neurology 86: 2295&#x2013;2302. 10.1212/WNL.0000000000002773</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002773</ArticleId><ArticleId IdType="pmc">PMC4909562</ArticleId><ArticleId IdType="pubmed">27194384</ArticleId></ArticleIdList></Reference><Reference><Citation>Bird SJ. 1985. Presymptomatic testing for Huntington's disease. J Am Med Assoc 253: 3286&#x2013;3291. 10.1001/jama.1985.03350460086027</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1985.03350460086027</ArticleId><ArticleId IdType="pubmed">3158756</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloch M, Hayden MR, Opitz JM. 1987. Preclinical testing in Huntington disease. Am J Med Genet 27: 733&#x2013;734. 10.1002/ajmg.1320270333</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.1320270333</ArticleId><ArticleId IdType="pubmed">2957915</ArticleId></ArticleIdList></Reference><Reference><Citation>Br&#xfc;ggemann N, Klein C. 2019. Will genotype drive treatment options? Mov Disord 10.1002/mds.27699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27699</ArticleId><ArticleId IdType="pubmed">30970153</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassidy MR, Roberts JS, Bird TD, Steinbart EJ, Cupples LA, Chen CA, Linnenbringer E, Green RC. 2008. Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease. Alzheimers Dement 4: 406&#x2013;413. 10.1016/j.jalz.2008.04.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2008.04.007</ArticleId><ArticleId IdType="pmc">PMC2610442</ArticleId><ArticleId IdType="pubmed">19012865</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao S, Roberts JS, Marteau TM, Silliman R, Cupples LA, Green RC. 2008. Health behavior changes after genetic risk assessment for Alzheimer disease: the REVEAL Study. Alzheimer Dis Assoc Disord 22: 94&#x2013;97. 10.1097/WAD.0b013e31815a9dcc</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e31815a9dcc</ArticleId><ArticleId IdType="pmc">PMC2483341</ArticleId><ArticleId IdType="pubmed">18317253</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen KD, Roberts JS, Whitehouse PJ, Royal CD, Obisesan TO, Cupples LA, Vernarelli JA, Bhatt DL, Linnenbringer E, Butson MB, et al. 2016. Disclosing pleiotropic effects during genetic risk assessment for Alzheimer disease: a randomized trial. Ann Intern Med 164: 155&#x2013;163. 10.7326/M15-0187</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M15-0187</ArticleId><ArticleId IdType="pmc">PMC4979546</ArticleId><ArticleId IdType="pubmed">26810768</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921&#x2013;923. 10.1126/science.8346443</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8346443</ArticleId><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Craufurd DI, Harris R. 1986. Ethics of predictive testing for Huntington's chorea: the need for more information. Br Med J (Clin Res Ed) 293: 249&#x2013;251. 10.1136/bmj.293.6541.249</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.293.6541.249</ArticleId><ArticleId IdType="pmc">PMC1341184</ArticleId><ArticleId IdType="pubmed">2942216</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook A, Williams K, Adams L, Blair I, Rowe DB. 2017. Predictive genetic testing for amyotrophic lateral sclerosis and frontotemporal dementia: genetic counselling considerations. Amyotroph Lateral Scler Frontotemporal Degener 18: 475&#x2013;485. 10.1080/21678421.2017.1332079</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1332079</ArticleId><ArticleId IdType="pubmed">28585888</ArticleId></ArticleIdList></Reference><Reference><Citation>Crozier S, Robertson N, Dale M. 2015. The psychological impact of predictive genetic testing for Huntington's disease: a systematic review of the literature. J Genet Couns 24: 29&#x2013;39. 10.1007/s10897-014-9755-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10897-014-9755-y</ArticleId><ArticleId IdType="pubmed">25236481</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Del-Aguila JL, Saef B, Black K, Fernandez MV, Budde J, Ibanez L, Deming Y, Kapoor M, Tosto G, et al. 2018. Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms. Alzheimers Dement 14: 205&#x2013;214. 10.1016/j.jalz.2017.08.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.08.013</ArticleId><ArticleId IdType="pmc">PMC5803427</ArticleId><ArticleId IdType="pubmed">28943286</ArticleId></ArticleIdList></Reference><Reference><Citation>Decruyenaere M, Evers-Kiebooms G, Cloostermans T, Boogaerts A, Demyttenaere K, Dom R, Fryns JP. 2004. Predictive testing for Huntington's disease: relationship with partners after testing. Clin Genet 65: 24&#x2013;31. 10.1111/j..2004.00168.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j..2004.00168.x</ArticleId><ArticleId IdType="pubmed">15032971</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo A, Klein C. 2018. Genetics of Parkinson disease. Handb Clin Neurol 147: 211&#x2013;227. 10.1016/B978-0-444-63233-3.00014-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-444-63233-3.00014-2</ArticleId><ArticleId IdType="pubmed">29325612</ArticleId></ArticleIdList></Reference><Reference><Citation>Escott-Price V, Sims R, Bannister C, Harold D, Vronskaya M, Majounie E, Badarinarayan N; GERAD/PERADES; IGAP consortia, Morgan K, Passmore P, et al. 2015. Common polygenic variation enhances risk prediction for Alzheimer's disease. Brain 138: 3673&#x2013;3684. 10.1093/brain/awv268</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv268</ArticleId><ArticleId IdType="pmc">PMC5006219</ArticleId><ArticleId IdType="pubmed">26490334</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanos JH, Gronka S, Wuu J, Stanislaw C, Andersen PM, Benatar M. 2011. Impact of presymptomatic genetic testing for familial amyotrophic lateral sclerosis. Genet Med 13: 342&#x2013;348. 10.1097/GIM.0b013e318204d004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/GIM.0b013e318204d004</ArticleId><ArticleId IdType="pmc">PMC4039017</ArticleId><ArticleId IdType="pubmed">21285887</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Opitz JM, Reynolds JF. 1986. Suicide and attempted suicide in Huntington disease: implications for preclinical testing of persons at risk. Am J Med Genet 24: 305&#x2013;311. 10.1002/ajmg.1320240211</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.1320240211</ArticleId><ArticleId IdType="pubmed">2940862</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples A, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. 1997. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. J Am Med Assoc 278: 1349&#x2013;1356. 10.1001/jama.1997.03550160069041</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1997.03550160069041</ArticleId><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Gargiulo M, Lejeune S, Tanguy ML, Lahlou-Lafor&#xea;t K, Faudet A, Cohen D, Feingold J, Durr A. 2009. Long-term outcome of presymptomatic testing in Huntington disease. Eur J Hum Genet 17: 165&#x2013;171. 10.1038/ejhg.2008.146</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejhg.2008.146</ArticleId><ArticleId IdType="pmc">PMC2986057</ArticleId><ArticleId IdType="pubmed">18716614</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannoccaro MP, Bartoletti-Stella A, Piras S, Pession A, De Massis P, Oppi F, Stanzani-Maserati M, Pasini E, Baiardi S, Avoni P, et al. 2017. Multiple variants in families with amyotrophic lateral sclerosis and frontotemporal dementia related to C9orf72 repeat expansion: further observations on their oligogenic nature. J Neurol 264: 1426&#x2013;1433. 10.1007/s00415-017-8540-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8540-x</ArticleId><ArticleId IdType="pubmed">28620717</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman JS, Hahn SE, Catania JW, LaRusse-Eckert S, Butson MB, Rumbaugh M, Strecker MN, Roberts JS, Burke W, Mayeux R, et al. 2011. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med 13: 597&#x2013;605. 10.1097/GIM.0b013e31821d69b8</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/GIM.0b013e31821d69b8</ArticleId><ArticleId IdType="pmc">PMC3326653</ArticleId><ArticleId IdType="pubmed">21577118</ArticleId></ArticleIdList></Reference><Reference><Citation>Gooding HC, Linnenbringer EL, Burack J, Roberts JS, Green RC, Biesecker BB. 2006. Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk. Patient Educ Couns 64: 259&#x2013;267. 10.1016/j.pec.2006.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pec.2006.03.002</ArticleId><ArticleId IdType="pubmed">16860524</ArticleId></ArticleIdList></Reference><Reference><Citation>Green RC, Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Brown T, Eckert SL, Butson M, Sadovnick AD, Quaid KA, et al. 2009. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med 361: 245&#x2013;254. 10.1056/NEJMoa0809578</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0809578</ArticleId><ArticleId IdType="pmc">PMC2778270</ArticleId><ArticleId IdType="pubmed">19605829</ArticleId></ArticleIdList></Reference><Reference><Citation>Grill JD, Bateman RJ, Buckles V, Oliver A, Morris JC, Masters CL, Klunk WE, Ringman JM; Dominantly Inherited Alzheimer's Network. 2015. A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease. Alzheimers Res Ther 7: 50 10.1186/s13195-015-0135-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-015-0135-0</ArticleId><ArticleId IdType="pmc">PMC4511231</ArticleId><ArticleId IdType="pubmed">26203303</ArticleId></ArticleIdList></Reference><Reference><Citation>Groves M. 2017. The highly anxious individual presenting for Huntington disease-predictive genetic testing: the psychiatrist's role in assessment and counseling. Handb Clin Neurol 144: 99&#x2013;105. 10.1016/B978-0-12-801893-4.00008-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-801893-4.00008-0</ArticleId><ArticleId IdType="pubmed">28947129</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellmuth J, Rabinovici GD, Miller BL. 2019. The rise of pseudomedicine for dementia and brain health. J Am Med Assoc 321: 543&#x2013;544. 10.1001/jama.2018.21560</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.21560</ArticleId><ArticleId IdType="pmc">PMC6579869</ArticleId><ArticleId IdType="pubmed">30681701</ArticleId></ArticleIdList></Reference><Reference><Citation>Huggins M, Bloch M, Kanani S, Quarrell OW, Theilman J, Hedrick A, Dickens B, Lynch A, Hayden M. 1990. Ethical and legal dilemmas arising during predictive testing for adult-onset disease: the experience of Huntington disease. Am J Hum Genet 47: 4&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1683755</ArticleId><ArticleId IdType="pubmed">1971997</ArticleId></ArticleIdList></Reference><Reference><Citation>Huntington's Disease Collaborative Research Group. 1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971&#x2013;983. 10.1016/0092-8674(93)90585-E</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(93)90585-E</ArticleId><ArticleId IdType="pubmed">8458085</ArticleId></ArticleIdList></Reference><Reference><Citation>Huntington's Disease Society of America. 1994. Guidelines for predictive testing for Huntington's disease. Huntington's Disease Society of America, New York.</Citation></Reference><Reference><Citation>Huntington's Disease Society of America. 2016. Genetic testing protocol for Huntington's disease. Huntington's Disease Society of America, New York.</Citation></Reference><Reference><Citation>Ibisler A, Ocklenburg S, Stemmler S, Arning L, Epplen JT, Saft C, Hoffjan S. 2017. Prospective evaluation of predictive DNA testing for Huntington's disease in a large German center. J Genet Couns 26: 1029&#x2013;1040. 10.1007/s10897-017-0085-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10897-017-0085-8</ArticleId><ArticleId IdType="pubmed">28361381</ArticleId></ArticleIdList></Reference><Reference><Citation>International Huntington Association and the World Federation of Neurology Research Group on Huntington's Chorea. 1994. Guidelines for the molecular genetics predictive test in Huntington's disease. J Med Genet 31: 555&#x2013;559. 10.1136/jmg.31.7.555</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.31.7.555</ArticleId><ArticleId IdType="pmc">PMC1049979</ArticleId><ArticleId IdType="pubmed">7966192</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler S. 1987. Psychiatric implications of presymptomatic testing for Huntington's disease. Am J Orthopsychiatry 57: 212&#x2013;219. 10.1111/j.1939-0025.1987.tb03531.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1939-0025.1987.tb03531.x</ArticleId><ArticleId IdType="pubmed">2954468</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler S, Field T, Worth L, Mosbarger H, Opitz JM, Reynolds JF. 1987. Attitudes of persons at risk for Huntington disease toward predictive testing. Am J Med Genet 26: 259&#x2013;270. 10.1002/ajmg.1320260204</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.1320260204</ArticleId><ArticleId IdType="pubmed">2949610</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolata G. 1986. Genetic screening raises questions for employers and insurers. Science 232: 317&#x2013;319. 10.1126/science.2938255</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.2938255</ArticleId><ArticleId IdType="pubmed">2938255</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamport AT, Opitz JM, Shaw MW. 1987. Presymptomatic testing for Huntington chorea: ethical and legal issues. Am J Med Genet 26: 307&#x2013;314. 10.1002/ajmg.1320260208</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.1320260208</ArticleId><ArticleId IdType="pubmed">2949614</ArticleId></ArticleIdList></Reference><Reference><Citation>Lannfelt L, Axelman K, Lilius L, Basun H. 1995. Genetic counseling in a Swedish Alzheimer family with amyloid precursor protein mutation. Am J Hum Genet 56: 332&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1801312</ArticleId><ArticleId IdType="pubmed">7825596</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson MU, Luszcz MA, Bui TH, Wahlin TB. 2006. Depression and suicidal ideation after predictive testing for Huntington's disease: a two-year follow-up study. J Genet Couns 15: 361&#x2013;374. 10.1007/s10897-006-9027-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10897-006-9027-6</ArticleId><ArticleId IdType="pubmed">16967331</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawson K, Wiggins S, Green T, Adam S, Bloch M, Hayden MR. 1996. Adverse psychological events occurring in the first year after predictive testing for Huntington's disease. The Canadian Collaborative Study Predictive Testing. J Med Genet 33: 856&#x2013;862. 10.1136/jmg.33.10.856</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.33.10.856</ArticleId><ArticleId IdType="pmc">PMC1050767</ArticleId><ArticleId IdType="pubmed">8933341</ArticleId></ArticleIdList></Reference><Reference><Citation>Lennox A, Karlinsky H, Meschino W, Buchanan JA, Percy ME, Berg JM. 1994. Molecular genetic predictive testing for Alzheimer's disease: deliberations and preliminary recommendations. Alzheimer Dis Assoc Disord 8: 126&#x2013;147. 10.1097/00002093-199408020-00009</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002093-199408020-00009</ArticleId><ArticleId IdType="pubmed">8060605</ArticleId></ArticleIdList></Reference><Reference><Citation>Lill CM. 2016. Genetics of Parkinson's disease. Mol Cell Probes 30: 386&#x2013;396. 10.1016/j.mcp.2016.11.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcp.2016.11.001</ArticleId><ArticleId IdType="pubmed">27818248</ArticleId></ArticleIdList></Reference><Reference><Citation>Lineweaver TT, Bondi MW, Galasko D, Salmon DP. 2014. Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults. Am J Psychiatry 171: 201&#x2013;208. 10.1176/appi.ajp.2013.12121590</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2013.12121590</ArticleId><ArticleId IdType="pmc">PMC4037144</ArticleId><ArticleId IdType="pubmed">24170170</ArticleId></ArticleIdList></Reference><Reference><Citation>Linnenbringer E, Roberts JS, Hiraki S, Cupples LA, Green RC. 2010. &#x201c;I know what you told me, but this is what I think:&#x201d; perceived risk of Alzheimer disease among individuals who accurately recall their genetics-based risk estimate. Genet Med 12: 219&#x2013;227. 10.1097/GIM.0b013e3181cef9e1</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/GIM.0b013e3181cef9e1</ArticleId><ArticleId IdType="pmc">PMC2921681</ArticleId><ArticleId IdType="pubmed">20139767</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Lopez C, Tariot PN, Caputo A, Langbaum JB, Liu F, Riviere ME, Langlois C, Rouzade-Dominguez ML, Zalesak M, Hendrix S, et al. 2019. The Alzheimer's Prevention Initiative Generation Program: study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease. Alzheimers Dement (N Y) 5: 216&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6562315</ArticleId><ArticleId IdType="pubmed">31211217</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLeod R, Tibben A, Frontali M, Evers-Kiebooms G, Jones A, Martinez-Descales A, Roos RA; Editorial Committee and Working Group &#x2018;Genetic Testing Counselling&#x2019; of the European Huntington Disease Network. 2013. Recommendations for the predictive genetic test in Huntington's disease. Clin Genet 83: 221&#x2013;231. 10.1111/j.1399-0004.2012.01900.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-0004.2012.01900.x</ArticleId><ArticleId IdType="pubmed">22642570</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, Chi&#xf2; A, Restagno G, Nicolaou N, Simon-Sanchez J, et al. 2012. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 11: 323&#x2013;330. 10.1016/S1474-4422(12)70043-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70043-1</ArticleId><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandich P, Mantero V, Verdiani S, Gotta F, Caponnetto C, Bellone E, Ferrandes G, Origone P. 2015. Complexities of genetic counseling for ALS: a case of two siblings with discordant genetic test results. J Genet Couns 24: 553&#x2013;557. 10.1007/s10897-015-9831-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10897-015-9831-y</ArticleId><ArticleId IdType="pubmed">25843563</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandich P, Lamp M, Gotta F, Gulli R, Iacometti A, Marchese R, Bellone E, Abbruzzese G, Ferrandes G. 2017. 1993&#x2013;2014: two decades of predictive testing for Huntington's disease at the Medical Genetics Unit of the University of Genoa. Mol Genet Genomic Med 5: 473&#x2013;480. 10.1002/mgg3.238</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mgg3.238</ArticleId><ArticleId IdType="pmc">PMC5606876</ArticleId><ArticleId IdType="pubmed">28944231</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshe VS, Gorbovskaya I, Kanji S, Kish M, M&#xfc;ller DJ. 2019. Clinical implications of APOE genotyping for late-onset Alzheimer's disease (LOAD) risk estimation: a review of the literature. J Neural Transm 126: 65&#x2013;85. 10.1007/s00702-018-1934-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-018-1934-9</ArticleId><ArticleId IdType="pubmed">30382407</ArticleId></ArticleIdList></Reference><Reference><Citation>Marteau TM, Roberts S, LaRusse S, Green RC. 2005. Predictive genetic testing for Alzheimer's disease: impact upon risk perception. Risk Anal 25: 397&#x2013;404. 10.1111/j.1539-6924.2005.00598.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1539-6924.2005.00598.x</ArticleId><ArticleId IdType="pubmed">15876213</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, Schupf N. 1995. Apolipoprotein E and Alzheimer's disease: the implications of progress in molecular medicine. Am J Public Health 85: 1280&#x2013;1284. 10.2105/AJPH.85.9.1280</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/AJPH.85.9.1280</ArticleId><ArticleId IdType="pmc">PMC1615571</ArticleId><ArticleId IdType="pubmed">7661240</ArticleId></ArticleIdList></Reference><Reference><Citation>Molinuevo JL, Pintor L, Peri JM, Lle&#xf3; A, Oliva R, Marcos T, Blesa R. 2005. Emotional reactions to predictive testing in Alzheimer's disease and other inherited dementias. Am J Alzheimers Dis Other Demen 20: 233&#x2013;238. 10.1177/153331750502000408</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/153331750502000408</ArticleId><ArticleId IdType="pubmed">16136847</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison PJ, Harding-Lester S, Bradley A. 2011. Uptake of Huntington disease predictive testing in a complete population. Clin Genet 80: 281&#x2013;286. 10.1111/j.1399-0004.2010.01538.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-0004.2010.01538.x</ArticleId><ArticleId IdType="pubmed">20880124</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson AM, Rademakers R. 2016. What we know about TMEM106B in neurodegeneration. Acta Neuropathol 132: 639&#x2013;651. 10.1007/s00401-016-1610-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1610-9</ArticleId><ArticleId IdType="pmc">PMC5074873</ArticleId><ArticleId IdType="pubmed">27543298</ArticleId></ArticleIdList></Reference><Reference><Citation>Post SG, Whitehouse PJ, Binstock RH, Bird TD, Eckert SK, Farrer LA, Fleck LM, Gaines AD, Juengst ET, Karlinsky H, et al. 1997. The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. J Am Med Assoc 277: 832&#x2013;836. 10.1001/jama.1997.03540340066035</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1997.03540340066035</ArticleId><ArticleId IdType="pubmed">9052715</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian J, Wolters FJ, Beiser A, Haan M, Ikram MA, Karlawish J, Langbaum JB, Neuhaus JM, Reiman EM, Roberts JS, et al. 2017. APOE-related risk of mild cognitive impairment and dementia for prevention trials: an analysis of four cohorts. PLoS Med 14: e1002254 10.1371/journal.pmed.1002254</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002254</ArticleId><ArticleId IdType="pmc">PMC5360223</ArticleId><ArticleId IdType="pubmed">28323826</ArticleId></ArticleIdList></Reference><Reference><Citation>Quaid KA, Brandt J, Folstein SE. 1987. The decision to be tested for Huntington's disease. J Am Med Assoc 257: 3362 10.1001/jama.1987.03390240068015</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1987.03390240068015</ArticleId><ArticleId IdType="pubmed">2953913</ArticleId></ArticleIdList></Reference><Reference><Citation>Quaid KA, Eberly SW, Kayson-Rubin E, Oakes D, Shoulson I; Huntington Study Group PHAROS Investigators and Coordinators. 2017. Factors related to genetic testing in adults at risk for Huntington disease: the prospective Huntington at-risk observational study (PHAROS). Clin Genet 91: 824-831. 10.1111/cge.12893</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cge.12893</ArticleId><ArticleId IdType="pmc">PMC5392180</ArticleId><ArticleId IdType="pubmed">27740685</ArticleId></ArticleIdList></Reference><Reference><Citation>Relkin NR, Kwon YJ, Tsai J, Gandy S. 1996. The National Institute on Aging/Alzheimer's Association recommendations on the application of apolipoprotein E genotyping to Alzheimer's disease. Ann NY Acad Sci 802: 149&#x2013;176. 10.1111/j.1749-6632.1996.tb32608.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.1996.tb32608.x</ArticleId><ArticleId IdType="pubmed">8993494</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards F, Williams K. 2004. Impact on couple relationships of predictive testing for Huntington disease: a longitudinal study. Am J Med Genet A 126A: 161&#x2013;169. 10.1002/ajmg.a.20582</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.a.20582</ArticleId><ArticleId IdType="pubmed">15057981</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts JS, LaRusse SA, Katzen H, Whitehouse PJ, Barber M, Post SG, Relkin N, Quaid K, Pietrzak RH, Cupples LA, et al. 2003. Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease. Alzheimer Dis Assoc Disord 17: 86&#x2013;93. 10.1097/00002093-200304000-00006</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002093-200304000-00006</ArticleId><ArticleId IdType="pubmed">12794385</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts JS, Barber M, Brown TM, Cupples LA, Farrer LA, LaRusse SA, Post SG, Quaid KA, Ravdin LD, Relkin NR, et al. 2004. Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multisite, randomized clinical trial. Genet Med 6: 197&#x2013;203. 10.1097/01.GIM.0000132688.55591.77</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.GIM.0000132688.55591.77</ArticleId><ArticleId IdType="pubmed">15266207</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfeld A. 1984. At risk for Huntington's disease: who should know what and when? Hastings Cent Rep 14: 5&#x2013;8. 10.2307/3561179</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/3561179</ArticleId><ArticleId IdType="pubmed">6086548</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, et al. 1993. Association of apolipoprotein E allele &#x3b5;4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43: 1467&#x2013;1472. 10.1212/WNL.43.8.1467</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.43.8.1467</ArticleId><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider SA, Alcalay RN. 2017. Neuropathology of genetic synucleinopathies with parkinsonism: review of the literature. Mov Disord 32: 1504&#x2013;1523. 10.1002/mds.27193</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27193</ArticleId><ArticleId IdType="pmc">PMC5726430</ArticleId><ArticleId IdType="pubmed">29124790</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinbart EJ, Smith CO, Poorkaj P, Bird TD. 2001. Impact of DNA testing for early-onset familial Alzheimer disease and frontotemporal dementia. Arch Neurol 58: 1828&#x2013;1831. 10.1001/archneur.58.11.1828</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.58.11.1828</ArticleId><ArticleId IdType="pubmed">11708991</ArticleId></ArticleIdList></Reference><Reference><Citation>Suter S. 2019. Legal challenges in genetics, including duty to warn, duty to recontact, and genetic discriminations. Cold Spring Harb Perspect Med 10.1101/cshperspect.a036665</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a036665</ArticleId><ArticleId IdType="pmc">PMC7117950</ArticleId><ArticleId IdType="pubmed">31548231</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CH, Hyman BT, Tan JJX, Hess CP, Dillon WP, Schellenberg GD, Besser LM, Kukull WA, Kauppi K, McEvoy LK, et al. 2017. Polygenic hazard scores in preclinical Alzheimer disease. Ann Neurol 82: 484&#x2013;488. 10.1002/ana.25029</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25029</ArticleId><ArticleId IdType="pmc">PMC5758043</ArticleId><ArticleId IdType="pubmed">28940650</ArticleId></ArticleIdList></Reference><Reference><Citation>Tibben A. 2007. Predictive testing for Huntington's disease. Brain Res Bull 72: 165&#x2013;171. 10.1016/j.brainresbull.2006.10.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2006.10.023</ArticleId><ArticleId IdType="pubmed">17352941</ArticleId></ArticleIdList></Reference><Reference><Citation>Tibben A, Vegter-vd Vlis M, vd Niermeijer MF, Kamp JJ, Roos RA, Rooijmans HG, Frets PG, Verhage F. 1990. Testing for Huntington's disease with support for all parties. Lancet 335: 553 10.1016/0140-6736(90)90796-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0140-6736(90)90796-8</ArticleId><ArticleId IdType="pubmed">1968570</ArticleId></ArticleIdList></Reference><Reference><Citation>Tibben A, Stevens M, de Wert GM, Niermeijer MF, van Duijn CM, van Swieten JC. 1997. Preparing for presymptomatic DNA testing for early onset Alzheimer's disease/cerebral haemorrhage and hereditary Pick disease. J Med Genet 34: 63&#x2013;72. 10.1136/jmg.34.1.63</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.34.1.63</ArticleId><ArticleId IdType="pmc">PMC1050849</ArticleId><ArticleId IdType="pubmed">9032652</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosto G, Bird TD, Tsuang D, Bennett DA, Boeve BF, Cruchaga C, Faber K, Foroud TM, Farlow M, Goate AM, et al. 2017. Polygenic risk scores in familial Alzheimer disease. Neurology 88: 1180&#x2013;1186. 10.1212/WNL.0000000000003734</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003734</ArticleId><ArticleId IdType="pmc">PMC5373783</ArticleId><ArticleId IdType="pubmed">28213371</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Al-Chalabi A, Chio A, Hardiman O, Kiernan MC, Rohrer JD, Rowe J, Seeley W, Talbot K. 2017. Genetic screening in sporadic ALS and FTD. J Neurol Neurosurg Psychiatry 88: 1042&#x2013;1044. 10.1136/jnnp-2017-315995</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-315995</ArticleId><ArticleId IdType="pmc">PMC5740553</ArticleId><ArticleId IdType="pubmed">28642287</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyler A, Harper PS. 1983. Attitudes of subjects at risk and their relatives towards genetic counselling in Huntington's chorea. J Med Genet 20: 179&#x2013;188. 10.1136/jmg.20.3.179</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.20.3.179</ArticleId><ArticleId IdType="pmc">PMC1049042</ArticleId><ArticleId IdType="pubmed">6224012</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, DeJesus-Hernandez M, Rademakers R. 2012. How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders? Curr Opin Neurol 25: 689&#x2013;700. 10.1097/WCO.0b013e32835a3efb</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0b013e32835a3efb</ArticleId><ArticleId IdType="pmc">PMC3923493</ArticleId><ArticleId IdType="pubmed">23160421</ArticleId></ArticleIdList></Reference><Reference><Citation>Vernarelli JA, Roberts JS, Hiraki S, Chen CA, Cupples LA, Green RC. 2010. Effect of Alzheimer disease genetic risk disclosure on dietary supplement use. Am J Clin Nutr 91: 1402&#x2013;1407. 10.3945/ajcn.2009.28981</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/ajcn.2009.28981</ArticleId><ArticleId IdType="pmc">PMC2854909</ArticleId><ArticleId IdType="pubmed">20219963</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner KN, Nagaraja HN, Allain DC, Quick A, Kolb SJ, Roggenbuck J. 2018. Patients with sporadic and familial amyotrophic lateral sclerosis found value in genetic testing. Mol Genet Genomic Med 6: 224&#x2013;229. 10.1002/mgg3.360</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mgg3.360</ArticleId><ArticleId IdType="pmc">PMC5902388</ArticleId><ArticleId IdType="pubmed">29266834</ArticleId></ArticleIdList></Reference><Reference><Citation>Wild EJ, Tabrizi SJ. 2017. Therapies targeting DNA and RNA in Huntington's disease. Lancet Neurol 16: 837&#x2013;847. 10.1016/S1474-4422(17)30280-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30280-6</ArticleId><ArticleId IdType="pmc">PMC5604739</ArticleId><ArticleId IdType="pubmed">28920889</ArticleId></ArticleIdList></Reference><Reference><Citation>World Federation of Neurology Research Group on Huntington's Disease. 1990. Ethical issues policy statement on Huntington's disease molecular genetics predictive test. J Med Genet 27: 34&#x2013;38. 10.1136/jmg.27.1.34</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.27.1.34</ArticleId><ArticleId IdType="pmc">PMC1016877</ArticleId><ArticleId IdType="pubmed">2137881</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao E, Chen Q, Goldman AL, Tan HY, Healy K, Zoltick B, Das S, Kolachana B, Callicott JH, Dickinson D, et al. 2017. Late-onset Alzheimer's disease polygenic risk profile score predicts hippocampal function. Biol Psychiatry Cogn Neurosci Neuroimaging 2: 673&#x2013;679. 10.1016/j.bpsc.2017.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpsc.2017.08.004</ArticleId><ArticleId IdType="pubmed">29560901</ArticleId></ArticleIdList></Reference><Reference><Citation>Zallen DT. 2018. &#x201c;Well, good luck with that&#x201d;: reactions to learning of increased genetic risk for Alzheimer disease. Genet Med 20: 1462&#x2013;1467. 10.1038/gim.2018.13</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2018.13</ArticleId><ArticleId IdType="pubmed">29517767</ArticleId></ArticleIdList></Reference><Reference><Citation>Zick CD, Mathews CJ, Roberts JS, Cook-Deegan R, Pokorski RJ, Green RC. 2005. Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior. Health Aff (Millwood) 24: 483&#x2013;490. 10.1377/hlthaff.24.2.483</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.24.2.483</ArticleId><ArticleId IdType="pmc">PMC1761120</ArticleId><ArticleId IdType="pubmed">15757934</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>